For most of the last decade, Merck ran a tidy business: one blockbuster drug, Keytruda, growing fast enough to carry everything else. Then 2026 arrived, and the company spent more than $15 billion in a single year on acquisitions and licensing deals, a sum larger than what the whole business earns in net income. That is not the behavior of a company riding high. It is the behavior of a company racing a clock.
The heart of it
The math, meaning what the filed numbers actually show, is a profitable business with a healthy net margin and growing revenue. The mood, meaning what the market pays today, is calm: a price-to-earnings multiple sitting right at Merck’s own decade median. But the price-to-sales multiple sits at the 96th percentile of its own history, which means the market is paying a near-record premium for each dollar of revenue at the exact moment that revenue’s most important source, Keytruda, faces a patent expiration in December 2028. Those two readings cannot both be right, and the gap between them is the story.
The clock on the shelf
Keytruda is the world’s best-selling oncology drug, with 2025 sales of $31.7 billion, more than half of Merck’s total revenue. Its primary U.S. compound patent expires in December 2028, per Patenta’s patent analysis. Related patents may push protection into late 2029, but the window is closing. Meanwhile, Januvia and Janumet, two older diabetes drugs that once padded the revenue line, lost U.S. market exclusivity in mid-2026. The company’s second-largest revenue stream is already eroding. What replaces Keytruda when biosimilars arrive is the question every dollar Merck spent this year is trying to answer.
The patent cliff is not a distant abstraction. It is a scheduled event, roughly two years out, that could remove the engine from the car, a structural fact the filed timeline makes concrete.
Three bets, one year, $15 billion
Merck’s answer to that clock came in three installments. In January 2026, it completed the acquisition of Cidara Therapeutics, adding antiviral candidates to the pipeline. In March, it acquired Terns Pharmaceuticals, picking up an oral drug candidate for chronic myeloid leukemia. In September, it signed a licensing deal with SciBrunch Therapeutics for a preclinical KRAS inhibitor, a target that has frustrated oncology researchers for decades. Together, the 10-Q for the quarter ended September 30, 2026, records $15.1 billion in R&D charges from these three moves alone.
That $15.1 billion is not a capital investment that sits on the balance sheet and slowly depreciates. Under accounting rules, most of it flows directly through the income statement as an expense, which is why FY2023’s net margin collapsed to near zero after a similar acquisition wave, even as the underlying business was healthy. The same distortion is baked into 2026’s numbers. The business did not suddenly get worse. The accounting caught the spending.
Whether those bets pay off is genuinely unknown. Preclinical KRAS inhibitors have a long history of promising early data and disappointing late-stage results. The data cannot yet confirm that Cidara’s antiviral candidates will clear the FDA’s bar. What the filing does confirm is the size of the wager.
What is actually working
Two pipeline stories in the filing carry real, filed evidence behind them. The first is Keytruda’s own evolution. Merck is shifting the drug from an intravenous infusion, which requires a clinic visit, to a subcutaneous injection, meaning a shot under the skin that takes minutes. The new formulation, called Keytruda Qlex, grew from a small share of the Keytruda family in the second quarter of 2026 to $830 million in Q3 2026 sales. A faster, more convenient delivery method is harder for a biosimilar to replicate immediately, which gives Merck a modest runway beyond the compound patent date.
The second is sac-TMT in endometrial cancer. The FDA accepted a Priority Review application with a decision date of June 15, 2027, after trial data showed a 32% reduction in the risk of death. Separately, Merck’s collaboration with Moderna on a personalized melanoma vaccine, intismeran, showed a 42% cut in recurrence or death risk, with a regulatory filing targeted for 2026. These are not preclinical hopes. They are late-stage results with filed evidence behind them.
The near-term pipeline carries genuine wins in the filed data. The open analytical question is whether they are large enough, and arrive fast enough, to offset the revenue hole Keytruda’s patent expiration would leave.
Reading the numbers
- $15.1 billion in 2026 R&D charges (from the Q3 2026 10-Q). What it is: the accounting cost of three acquisitions and one licensing deal, expensed immediately. What it means here: it will suppress reported earnings for 2026 the same way a $1.4 billion charge suppressed FY2023’s margin to near zero, even though the underlying business kept generating cash. Everyday version: a household earning $100,000 a year that spends $30,000 on a single home repair looks broke on paper that year, but the house is still standing.
- 28.1% net margin in FY2025 (from the FY2025 10-K). What it is: for every dollar of sales, Merck kept 28 cents after all costs. What it means here: the core business is genuinely profitable, which is what funds the $15 billion spending spree. Everyday version: a restaurant that clears 28 cents on every dollar of food sold can afford to renovate the kitchen without borrowing.
- P/S at the 96th percentile of its own decade (BullScope Valuation Database, methodology at bullscope.ai/methodology/valuation-database; calculated from monthly closing price and trailing-twelve-month revenue, 2015–2025). What it is: the price-to-sales ratio, meaning the market’s price tag per dollar of revenue, sits higher than 96 of the last 100 comparable readings in Merck’s own history. What it means here: the market is paying a near-record premium for revenue that is about to face its biggest structural threat. Everyday version: paying a near-record price for a lease on a building whose anchor tenant has announced they are leaving in two years.
For the standing yardsticks on Merck & Co: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Merck & Co.
Sources
- Merck 10-Q, quarter ended September 30, 2026 (SEC EDGAR)
- Merck 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- Merck 10-K, fiscal year ended December 31, 2023 (SEC EDGAR)
- Merck acquisitions, Tracxn
- Merck/SciBrunch licensing deal, MarketScreener
- Keytruda patent timeline, Patenta
- Drug patent cliff 2026 to 2028, Patenta
- FDA traditional approval for pembrolizumab in TMB-H solid tumors








